Rotavirus A serotype G2 (RVA G2)

Rotavirus serotype G2 is a specific antigenic classification of Rotavirus A, primarily defined by the VP7 glycoprotein located on the outer capsid of the virus. It is a major cause of severe, dehydrating gastroenteritis in infants and young children worldwide, often circulating in combination with the P[4] genotype (NCBI, 2023). As a double-stranded RNA virus, it infects the enterocytes of the small intestine, leading to malabsorption and secretory diarrhea through the action of viral proteins like NSP4 (PubMed, 2021). Therapeutic strategies primarily focus on prevention through live-attenuated oral vaccines, such as RotaTeq and Rotarix, which aim to elicit a protective immune response against common G-serotypes including G2 (WHO, 2021). Monitoring G2 prevalence is critical for assessing vaccine efficacy, as some vaccines have historically shown varying levels of effectiveness against G2 compared to other serotypes like G1 (CDC, 2023).

Other names

G2 rotavirusRotavirus A G2 genotypeOuter capsid glycoprotein VP7 (G2)Human rotavirus G2G2P[4] rotavirus

Vaccines targeting Rotavirus serotype G2 work by inducing active immunity through the production of neutralizing antibodies, specifically targeting the VP7 (G-type) and VP4 (P-type) outer capsid proteins to prevent viral attachment and entry into intestinal enterocytes (CDC, 2023; WHO, 2021). Antiviral agents like Nitazoxanide may inhibit viral replication by interfering with the maturation of viral proteins (NCBI, 2022).